RhumbLine Advisers
NPCE icon

RhumbLine Advisers’s Neuropace NPCE Stock Holding History

RhumbLine Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$387K Buy
29,446
+139
+0.5% +$2.08K ﹤0.01% 2768
2025
Q4 		$452K Sell
29,307
-2,726
-9% -$36.5K ﹤0.01% 2732
2025
Q3 		$330K Sell
32,033
-4,923
-13% -$46.4K ﹤0.01% 2930
2025
Q2 		$412K Buy
36,956
+19,729
+115% +$247K ﹤0.01% 2802
2025
Q1 		$212K Buy
17,227
+2,267
+15% +$28.4K ﹤0.01% 3078
2024
Q4 		$167K Buy
14,960
+634
+4% +$5.51K ﹤0.01% 3284
2024
Q3 		$99.8K Sell
14,326
-338
-2% -$2.47K ﹤0.01% 3495
2024
Q2 		$111K Buy
+14,664
New +$148K ﹤0.01% 3489

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RhumbLine Advisers's NPCE Position: Q1 2026 in Review

RhumbLine Advisers increased its Neuropace (NPCE) stake by 0.47% in Q1 2026, buying an estimated $2.08K and bringing the position to 29,446 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

RhumbLine Advisers first reported a position in NPCE in Q2 2024 and has held it in 8 quarters since. The position peaked at $452K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • RhumbLine Advisers held 29,446 shares of Neuropace worth $387K as of Q1 2026.
  • RhumbLine Advisers bought 139 Neuropace shares in Q1 2026, an estimated $2.08K.
  • Neuropace made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2768 holding.
  • RhumbLine Advisers first reported a position in Neuropace in Q2 2024 and has held it in 8 quarters since.
  • RhumbLine Advisers's Neuropace position peaked at $452K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.